SYBD have Synthetic Blood International Inc. exposed to more stock investors 800.940.6559.

Synthetic Blood International Inc. Details:

Synthetic Blood International, Inc. develops biotechnology products. It focuses on developing Oxycyte, a product alternative to transfused blood for use in surgical and similar medical situations. Oxycyte blood substitute product is a perfluorocarbon emulsified with water and a surfactant, which is provided to the patient intravenously. The properties of perfluorocarbon enable the product to gather oxygen from the lungs and transport the oxygen through the body releasing it along the way. Oxycyte is intended as a transfusion substitute for blood transfusion that ordinarily would be applied in cases of trauma, surgery (emergency and elective), unexpected blood loss, and other general medical ...

May 17, 2008 2:46 AM ET

HEALTH CARE SECTOR

BIOTECHNOLOGY INDUSTRY

Synthetic Blood International Inc.

(SYBD:OTC BB)

LAST $0.86 USD

CHANGE TODAY -0.015 -1.71%

VOLUME 571.9K

SYBD On Other Exchanges

As of 3:59 PM 05/16/08 All times are local (Market data by Reuters is delayed by at least 15 minutes).

OPEN $0.87		PREVIOUS CLOSE $0.88
DAY HIGH $0.88		DAY LOW $0.84
52 WEEK HIGH 03/28/08 - $1.01		52 WEEK LOW 09/21/07 - $0.07
MARKET CAP 121.1M		AVERAGE VOLUME 3 mo 663.7K
DILUTED EPS TTM $-0.05		SHARES OUTSTANDING 140.9M
SYBD Does Not Pay Dividends		P/E TTM NM
K = Thousands M = Millions B = Billions

SYBD Details

Detailed Description...

www.sybd.com

6 Employees

Founded in 1967

Latest 10-K

Latest 10-Q

More SEC Filings...

Top Compensated Officers

Dr. Richard Kiral Ph.D.

President, Chief Operating Officer and Direct...

Age: 65

Total Annual Compensation: $152.8K

Executives, Board Directors

Compensation as of Fiscal Year 2007.

Key developments

Synthetic Blood International Inc. to Open New Research Office at Virginia Biotechnology Research Park

05/7/2008

Synthetic Blood International Inc. announced that it has signed an agreement to lease space for a research office in the Virginia BioTechnology Research Park, located in Richmond, VA. This space will be used to coordinate research between the company and sponsored researchers at Virginia Commonwealth University Reanimation Engineering Shock Center (VCURES). A number of pre-clinical and clinical projects utilizing Oxycyte(R) are presently underway and others are planned at VCURES. Oxycyte is the Company´s perfluorocarbon (PFC) therapeutic oxygen carrier and blood substitute.

Synthetic Blood International Inc. has Changed its Name to Oxygen Biotherapeutics, Inc

04/22/2008

Synthetic Blood International Inc. changed its name to Oxygen Biotherapeutics Inc.

Synthetic Blood International Inc., Annual General Meeting, Jun 17, 2008

04/22/2008

Synthetic Blood International Inc., Annual General Meeting, Jun 17, 2008 Agenda: To approve a name change among other issues in the proxy statement; to approve a change in the company´s state of incorporation and an increase in the number of authorized shares.

SYBD, chart, Synthetic Blood International Inc.

Stock Quotes

Recently Viewed
SYBD	$0.86 USD	-0.015

Market data is delayed at least 20 minutes.

Competitors

Company	Last	Change
Alliance Pharmaceutical Corp	$0.03 USD	+0.002
Biopure Corp	$0.60 USD	-0.01
ImaRx Therapeutics Inc	$0.55 USD	+0.02
Sanguine Corp	$0.10 USD	+0.01
View Industry Companies
Market data is delayed at least 20 minutes.

Industry Analysis

Valuation	SYBD	Industry Range
Price/Earnings	NM	Not Meaningful
Price/Sales	--	Not Meaningful
Price/Book	NM	Not Meaningful
Price/Cash Flow	NM	Not Meaningful
TEV/Sales	--	Not Meaningful
SYBD

View More Transactions...